<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report five new cases of <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> (RMS) in <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>These cases, combined with those previously reported, increase the number of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> to 17 (10 RMSs, 3 <z:hpo ids='HP_0003006'>neuroblastomas</z:hpo>, 2 <z:hpo ids='HP_0002862'>bladder carcinomas</z:hpo>, 1 <z:hpo ids='HP_0009588'>vestibular schwannoma</z:hpo>, 1 epithelioma), in at least 100 known <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>Despite possible ascertainment bias, and the incomplete identification of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> patients, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> frequency could be as high as 17% </plain></SENT>
<SENT sid="3" pm="."><plain>This is comparable to the 7-21% frequency of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> in <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e> (BWS), and may justify <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> screening </plain></SENT>
<SENT sid="4" pm="."><plain>Based on the recommendations for screening BWS patients, we propose a screening protocol consisting of ultrasound examination of the abdomen and pelvis every 3-6 months until age 8-10 years for RMS and abdominal <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>; urine <z:chebi fb="2" ids="33567">catecholamine</z:chebi> metabolite analysis every 6-12 months until age 5 years for <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>; and urinalysis for <z:hpo ids='HP_0000790'>hematuria</z:hpo> annually for <z:hpo ids='HP_0002862'>bladder carcinoma</z:hpo> after age 10 years </plain></SENT>
<SENT sid="5" pm="."><plain>These recommendations may need to be modified, as new information becomes available </plain></SENT>
<SENT sid="6" pm="."><plain>Potential criticism of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> screening protocol concerns the lack of evidence for improved outcome, and possible overestimation of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> risk </plain></SENT>
<SENT sid="7" pm="."><plain>The ability of RMSs to occur at various sites complicates <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> screening, but 8 of the 10 RMSs in <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> patients originated from the abdomen, pelvis and urogenital area </plain></SENT>
<SENT sid="8" pm="."><plain>Prior diagnosis of <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> is a prerequisite for the implementation of any screening protocol </plain></SENT>
<SENT sid="9" pm="."><plain>The diagnosis of <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> should also be considered in individuals with RMS and physical findings suggestive of <z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> </plain></SENT>
</text></document>